Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11723116 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Rybalkin SD, et al. (2002) Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 277, 3310-7 11723116
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S102-p - PDE5A (human) ▲
Orthologous residues
PDE5A (human): S102‑p, PDE5A (mouse): S92‑p, PDE5A (rat): S60‑p, PDE5A (cow): S92‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  uterus
 Cellular systems studied:  primary cultured cells
 Species studied:  human
 Comments:  uterine smooth muscle cells
 Enzymes shown to modify site in vitro: 
Type Enzyme
PHOSPHATASE PPP1CA (human)
KINASE PKACa (human)
KINASE PKG1 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cGMP analog increase
calyculin A cGMP analog augment treatment-induced increase
okadaic acid cGMP analog augment treatment-induced increase
cAMP analog no change compared to control

S92-p - PDE5A (mouse) ▲
Orthologous residues
PDE5A (human): S102‑p, PDE5A (mouse): S92‑p, PDE5A (rat): S60‑p, PDE5A (cow): S92‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  VSMC-aorta, VSMC-aorta [PKG1 (mouse)]
 Cellular systems studied:  primary cells
 Species studied:  mouse
 Comments:  PKG1 -/- and wt aorta smooth muscle cells
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKG1 (mouse) pharmacological activator of upstream enzyme, genetic knockout/knockin of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cGMP analog increase
calyculin A cGMP analog augment treatment-induced increase
okadaic acid cGMP analog augment treatment-induced increase
cAMP analog no change compared to control


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.